IXB.SI IX Biopharma Ltd Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
13:05
Sep 08
Sep 08
US government contract and EUA progress drive potential growth for IX Biopharma.
IX Biopharma has secured a $41 million sole-source contract from the US Defense Health Agency to fund Phase 3 trials and regulatory work. The company is currently pursuing an Emergency Use Authorization for its product, with a submission expected in Q4 2026. The primary risk is the execution of the regulatory process and the dependency on US government procurement.
HIGH
About IXB.SI Analyst Coverage
Buzzberg tracks IXB.SI (IX Biopharma Ltd) across 1 sources. 1 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (100%). 1 total trade idea tracked. Past 7 days: 1 bullish. Latest voices: u/rarrarrar91.